Stool Antigen Testing Market Report: Market Size & Forecast 2026

Stool antigen testing encompasses diagnostic assays that detect specific antigens in fecal samples, most notably for Helicobacter pylori, a bacterium linked to peptic ulcers and gastric cancer. The market spans various test formats, with enzyme immunoassays and immunochromatographic rapid tests representing the dominant technologies used in clinical laboratories, hospitals, and point-of-care settings. Rising global incidence of gastrointestinal infections and greater emphasis on early, non-invasive screening are expanding clinical adoption of these diagnostic tools.

• •Market valued at approximately $1.7 billion in 2025 with a projected 7.0% annual growth rate through the early 2030s
• •H. pylori stool antigen testing represents the largest single application segment within the broader market
• •Clinical demand is driven by the ability to detect infections without invasive endoscopic procedures

The high global prevalence of H. pylori infection, estimated to affect roughly half the world's population, creates sustained demand for reliable, non-invasive diagnostic options. Increasing adoption of point-of-care testing in outpatient settings is accelerating market expansion by enabling faster clinical decision-making. Additionally, favorable reimbursement policies in developed markets and national screening programs targeting gastric cancer prevention in high-burden countries are significant demand catalysts.

• •H. pylori infection affects an estimated 50% of the global population, creating durable baseline demand for antigen-based diagnostics
• •Point-of-care stool antigen testing is gaining momentum as it delivers results in minutes without laboratory infrastructure requirements
• •Government-backed H. pylori screening programs, particularly across Asia-Pacific and parts of Eastern Europe, are driving institutional procurement

The market is commonly segmented by test type, including bacterial antigen detection, parasitic antigen detection, and viral antigen panels, as well as by technology platform, including enzyme immunoassays and immunochromatographic assays. End-use segments include hospitals, diagnostic laboratories, and point-of-care facilities. Geographically, North America holds a significant share due to established healthcare infrastructure and high awareness, while Asia-Pacific is the fastest-growing region owing to high H. pylori prevalence and expanding healthcare access.

• •Enzyme immunoassays hold the largest technology segment share due to their established clinical accuracy and laboratory workflow integration
• •North America leads the global market, supported by advanced diagnostic infrastructure and high per-capita healthcare spending
• •Asia-Pacific is the fastest-growing regional market, driven by high H. pylori endemicity in countries including China, India, and Japan

What are the recent trends and outlook?

The market outlook through 2031 remains constructive, with consistent 7% annual growth expected as non-invasive diagnostic preference solidifies and new product innovations emerge. Multiplex GI panel testing is a notable emerging trend, enabling simultaneous detection of multiple pathogens from a single stool sample. Advances in lateral flow assay technology are improving point-of-care test accuracy and accessibility in low-resource settings, expanding the total addressable market beyond traditional clinical environments.

• •Multiplex gastrointestinal testing panels are emerging as a key trend, allowing comprehensive pathogen screening from a single sample
• •Improved immunochromatographic assay designs are narrowing the performance gap between point-of-care and laboratory-based testing
• •The broader $5+ billion GI diagnostics market, encompassing stool testing beyond antigen detection, is expected to sustain strong investment and product development activity